Assenagon Asset Management S.A. Larimar Therapeutics, Inc. Transaction History
Assenagon Asset Management S.A.
- $54.8 Billion
- Q1 2025
A detailed history of Assenagon Asset Management S.A. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 218,434 shares of LRMR stock, worth $417,208. This represents 0.0% of its overall portfolio holdings.
Number of Shares
218,434
Previous 219,987
0.71%
Holding current value
$417,208
Previous $840,000
44.17%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding LRMR
# of Institutions
123Shares Held
66.7MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$40.6 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$12.3 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$11.5 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$8.89 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$7.93 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $82.6M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...